ATARA BIOTHERAPEUTICS, INC.
Moat Score — Atara Biotherapeutics, Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Atara holds patents covering its allogeneic, EBV-specific T-cell manufacturing platform, and has already achieved European regulatory approval (Ebvallo) for tabelecleucel, providing legally and clinically validated intellectual property protection around a genuinely differentiated technology. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Allogeneic cell therapy manufacturing remains complex and costly to scale, and Atara has not yet demonstrated a durable manufacturing cost advantage over other cell therapy platforms. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As an approved therapy addressing a rare, life-threatening condition with no directly comparable off-the-shelf alternative, tabelecleucel can command premium specialty pricing in Europe, a dynamic likely to extend to the U.S. if approved. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Cell therapy development and treatment exhibits no network effect between patients or providers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once transplant centers integrate tabelecleucel into treatment protocols for EBV+ PTLD, there is some institutional and physician familiarity lock-in, though this is limited given the absence of many currently approved direct alternatives to switch from. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The off-the-shelf allogeneic cell therapy space remains an emerging, relatively uncrowded niche, giving Atara some first-mover positioning, though the rare-disease nature of its lead indication limits how large an efficient-scale advantage can become without pipeline expansion. |